ERBB2 and breast cancer: In particular, the receptor status classifies BC into four categories, i.e., Luminal A, Luminal B, Human epidermal growth factor receptor 2 (HER-2)+, and triple negative (TNBC), and also influences the choice of treatment options and the prediction of survival [2,3].